Chicken IL-26 regulates immune responses through the JAK/STAT and NF-kB signaling pathways

Chicken interleukin 26 (ChIL-26), a member of the IL-10 family, is expressed in T cells and can induce expression of proinflammatory cytokines. We examined the response of signal transduction pathways to ChIL-26 stimulation in the chicken T(CU91), macrophage (HD11), and fibroblast (OU2) cell lines....

Full description

Saved in:
Bibliographic Details
Published inDevelopmental and comparative immunology Vol. 73; p. 10
Main Authors Truong, Anh Duc, Hong, Yeojin, Hoang, Cong Thanh, Lee, Janggeun, Hong, Yeong Ho
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Science Ltd 01.08.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chicken interleukin 26 (ChIL-26), a member of the IL-10 family, is expressed in T cells and can induce expression of proinflammatory cytokines. We examined the response of signal transduction pathways to ChIL-26 stimulation in the chicken T(CU91), macrophage (HD11), and fibroblast (OU2) cell lines. ChIL-26 activated JAK2 and TYK2 phosphorylation, as well as activation of STAT1, STAT3, and SHP2 via tyrosine/ serine residues. We also showed that ChIL-26 activates the phosphorylation of NF-KB1, TAKI, and MyD88 kinase, which are key regulators of NF-KB signaling pathways. Moreover, ChIL-26 stimulation upregulated mRNA expression of chemokines (CCL4, CCL2O, and CXCL14), Thi (IFN-α, IFN-β, IFN-y, IL-1β, and IL- 6), Th2 (IL-4 and IL-10), and Th17 (IL-12p40, IL-17A, and IL-17F), and the Treg cytokines (TGF-(β4); additionally, it increased Th1 and Th17 protein levels and nitric oxide production but did not affect cell proliferation. Together, these results suggest that ChIL-26-induced activation of chemokines, Th1, Th2, and, Th17, and the Treg cytokines is mediated through JAK/STAT and NF-KB signaling pathways in chicken T, macrophage, and fibroblast cell lines. These results indicate a key role for ChIL-26-induced polarization of the immune response and could reveal new therapeutic approaches for use in combination with molecules that activate T and macrophage cells via activation JAK/STAT and NF-KB signaling pathways.
ISSN:0145-305X
1879-0089